Conference Coverage

Transgender youth on hormone therapy risk substantial bone loss


 

FROM ENDO 2022

Monitor bone in transgender youth; Use vitamin D and weight-bearing exercise

Dr. O’Connell is the first author of a recent summary of the pharmacologic management of trans and gender-diverse adolescents. That summary covered multiple topics in addition to risk of bone loss, including the impact on growth, cognition, and mental health (J Clin Endocrinol Metab. 2022 Jan;107:241-257).

Overall, she believes that bone health should be monitored for children receiving puberty-delaying or gender-affirming therapies but agrees with Dr. Nokoff that the clinical impact remains poorly defined.

“Long-term follow-up studies will be required to assess the impact, if any, on functional outcomes such as fracture risk,” she reported. Still, she encouraged use of standard ways of improving bone health, including adequate vitamin D intake and weight-bearing exercise.

Dr. Nokoff and Dr. O’Connell have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Doctors have failed them, say those with transgender regret
MDedge Endocrinology
More medical schools build training in transgender care
MDedge Endocrinology
Trans women in female sports: A sports scientist’s take
MDedge Endocrinology
Few children with early social gender transition change their minds
MDedge Endocrinology
New studies show growing number of trans, nonbinary youth in U.S.
MDedge Endocrinology
A ‘crisis’ of suicidal thoughts, attempts in transgender youth
MDedge Endocrinology
Biden boosts LGBTQIA+ protections, bans conversion therapy
MDedge Endocrinology
AMA: Insurance should cover treatment for infertility caused by gender-affirming care
MDedge Endocrinology
LGBTQ students would get new protections under Biden plan
MDedge Endocrinology
Alabama cites Roe decision in call to ban transgender health care
MDedge Endocrinology